• Profile
Close

Dupilumab in children with uncontrolled moderate-to-severe asthma

New England Journal of Medicine Dec 13, 2021

Bacharier LB, Maspero JF, Katelaris CH, et al. - Treatment with add-on dupilumab (monoclonal antibody) was associated with fewer asthma exacerbations and better lung function and asthma control than placebo in children with uncontrolled moderate-to-severe asthma.

  • A 52-week phase 3, randomized, double-blind, placebo-controlled trial of 408 children with uncontrolled moderate-to-severe asthma randomized to a subcutaneous injection of dupilumab or matched placebo every 2 weeks; all patients continued to receive a stable dose of standard background therapy.

  • Among those with type 2 inflammatory phenotype, the annualized rate of severe asthma exacerbations was 0.31 and 0.75 with dupilumab and with placebo, respectively (relative risk reduction in the dupilumab group, 59.3%).

  • Dupilumab-induced mean (±SE) change from baseline in the percentage of predicted prebronchodilator forced expiratory volume in 1 second was 10.5±1.0 percentage points; it was 5.3±1.4 percentage points with placebo (mean difference, 5.2 percentage points).

  • Significantly better asthma control was achieved with dupilumab use vs placebo.

  • The two groups showed similar incidence of serious adverse events.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay